News

Frahad Ravandi-Kashani, MD, had the chance to discuss the role of MRD in treating patients with hairy cell leukemia.

New therapeutic options are emerging for patients with Lung cancer positive for ALK or ROS1.

The NDA for Blueprint Medicines' agent avapritinib will be split into two separate submissions for patients with GIST.

An update to the biologics license application of eflapegrastim has been resubmitted to the FDA to include chemo-induced neutropenia.

Following concerns over breast implant-associated cancer and illnesses, the Food and Drug Administration issued draft guidelines for additional labeling measures on devices.

Results from the phase III CARD trial suggest positive outcomes for patients with advanced prostate cancer on a novel treatment chemotherapy combination therapy treatment.

At the 2019 ESMO Congress, the phase II KATE2 trial missed its primary endpoint but found promising results for a subgroup of patients with HER2-positive breast cancer with a PD-L1 expression.

The FDA approves the use of niraparib in the treatment of patients with HRD-positive advanced ovarian cancer based on results from the phase II QUADRA study.

The FDA has expanded the approval of aprepitant to include in its label the use of a single dose regimen in patients receiving moderately epigenetic chemotherapy.

Immunotherapy is sometimes considered solely for the later stages of treatment, but findings from a new study show promise for immunotherapy in treating patients with early breast cancer.

ACCC is celebrating the 15th anniversary of Oncology Pharmacy Education Network by honoring its founders.

Stress management is vital for any profession, but for oncology nurses, stress management is crucial to not only helping themselves but also helping their patients.

Looking at biomarkers PD-L1 and TMB in tandem can help predict a patient with NSCLC reaction to immunotherapy.

A label update from the FDA has approved a sBLA for romiplostim to include data demonstrating sustained platelet responses in adults with ITP.

By implementing a survivorship program at their cancer center, oncology nurses were able to improve the quality of life in patients with recurrent breast cancer.

The FDA has granted a priority review for Trastuzumab Deruxtecan to treat HER2-positive metastatic breast cancer based on the results from two new studies.

At the 2019 ESMO Congress, results for the MONALEESA-3 trial showed promise for patients with breast cancer and had many experts excited over its clinical implications.

In this month’s episode of CURE Talks Cancer Podcast: Nursing Edition, we had the chance to speak with Chasity M. Washington, MPH, CHES, on how the diversity in the workplace is important to cancer care.

A closer look at the genealogy of Utah's founders provided one expert with a data mine to help combat lung cancer.

Management of axillary lymph nodes in patients with breast cancer has undergone some positive changes, but more research is required to treat this patient population properly.

Partial-breast radiation may be more convenient for patients with breast cancer, and according to recent research, the outcomes aren’t much different than patients who had whole-breast radiation.

Patients with a higher likelihood to develop BRCA 1 or BRCA 2 mutations are slipping through the cracks, making testing for these mutations a vital part of any breast cancer treatment plan.

Even if survivors of pediatric neuroblastoma received treatment before 1 year old, they are still at risk for cognitive issues years later.

A study of patients with chronic lymphocytic leukemia looked into the role of treatment and disease itself in cognitive impairment.

Malnutrition is a potentially fatal adverse event that many patients undergoing treatment for cancer will face, but it's an adverse event that can be dealt with ahead of time during the first visit with an oncology nurse.

Here are the top 5 Oncology Nursing News stories for September 2019.

At the 2019 European Society for Medical Oncology, new study results showed promise for a frontline combination therapy for patients with newly diagnosed, advanced ovarian cancer.

After being diagnosed with essential thrombocythemia, former NHL referee Kerry Fraser did his best to maintain a positive attitude – and he says his oncology nurses played a huge role in that.